Isolation and partial characterization of the adduct formed by 13-hydroxyellipticine with deoxyguanosine in DNA

Neuroendocrinology Letters

Volumn 29, Issue 5, 2008, Pages 728-732

  Moserová, Michaela ^a   Kotrbová, Věra ^a   Rupertová, Martina ^a   Naiman, Karel ^a   Hudeček, Jiří ^a   Hodek, Petr ^a   Frei, Eva ^b   Stiborová, Marie ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

13 hydroxyellipticine; Anticancer drug; DNA adducts; Ellipticine; HPLC

Indexed keywords

13 HYDROXYELLIPTICINE; ACETIC ACID; ACETYL COENZYME A; ACYLTRANSFERASE; ADENOSINE 3' PHOSPHATE 5' PHOSPHOSULFATE; DEOXYGUANOSINE; DNA; ELLIPTICINE; ELLIPTICINE 13 YLIUM; ELLIPTICINE DERIVATIVE; N,O ACYLTRANSFERASE 1; N,O ACYLTRANSFERASE 2; PHOSPHORUS 32; SULFATE; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 1A2; UNCLASSIFIED DRUG;

ALKALINITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; DNA ADDUCT; DNA DETERMINATION; DNA ISOLATION; DNA STRUCTURE; DRUG CONJUGATION; DRUG DNA BINDING; DRUG MECHANISM; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY;

EID: 57149128596     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Auclair C. Multimodal action of antitumor agents on DNA: The ellipticine series. Arch Biochem Biophys 1985; 259: 1-14.
2. Bořek-Dohalská L, Frei E., Stiborová M. DNA adduct formation by the anticancer drug ellipticine and its hydroxy derivatives in human breast adenocarcinoma MCF-7 cells. Collect Czech Chem Commun 2004; 69: 603-615.
3. Donaghy M.J., Stanforch S.P. Nucleophilic addition of fused benzimidazole N-oxide. Tetrahedron 1999; 55: 1441-1448.
4. Dračínský M., Sejbal J., Rygerová B., Stiborová M. An efficient modification of ellipticine synthesis and preparation of 13-hydroxyellipticine. Tetrahetron Lett 2007; 48: 6893-6895.
5. Frei E, Bieler C, Arlt VM, Wiessler M, Stiborová M. Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. Biochem Pharmacol 2002; 64: 289-295.
6. Kotrbová V., Aimová D., Březinová A., Janouchová K.., Poljaková J., Hodek P., Frei E., Stiborová M. Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes. Neuro Endocrinol Lett 2006; 27 (Suppl. 2): 18-20.
7. Poljaková J, Dračínský M, Frei E, Hudeček J, Stiborová M. The effect of pH on peroxidase-mediated oxidation of and DNA adduct formation by ellipticine. Collect Czech Chem Commun 2006; 71: 1169-1185.
8. Poljaková J., Frei E., Gomez J.E., Aimová D., Eckschlager T., Hraběta J., Stiborová M. DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells. Cancer Lett 2007; 252: 270-279.
9. Stiborová M., Arlt V.M., Henderson C.J., Wolf C.R., Kotrbová V., Moserová M., Hudeček J., Phillips D.H., Frei E. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH: cytochrome P450 reductase null mouse. Toxicol Appl Pharmacol 2008; 226: 318-327.
10. Stiborová M, Bieler CA, Wiessler M, Frei E. The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol 2001; 62: 1675-1684.
11. 32P-postlabeling. Int J Cancer 2003; 107: 885-890.
12. 5. Neuro Endocrinol Lett 2006; 27(Suppl. 2): 35-39.
13. Stiborová M, Poljaková J, Ryšlavá H, Dračínský M, Eckschlager T, Frei E. Mammalian peroxidases activate ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine. Int J Cancer 2007; 120: 243-251.
14. Stiborová M., Rupertová M., Aimová D., Ryšlavá H., Frei E. Formation and persistence of DNA adducts of anticancer drug ellipticine in rats. Toxicology 2007; 236: 50-60.
15. Stiborová M, Rupertová M, Schmeiser HH, Frei E. Molecular mechanism of antineoplastic action of an anticancer drug ellipticine. Biomed. Pap 2006; 150: 13-23.
16. 2-oxide. Cancer Res 2004; 64: 8374-8380.
17. Stiborová M, Stiborová-Rupertová M, Bořek-Dohalská L, Wiessler M, Frei E. Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem Res Toxicol 2003; 16: 38-47.
18. Williams J.A., Phillips D.H. Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer. Cancer Res 2000; 60: 4667-77.